Bioclinic Naturals 5-HTP 100mg (60 enteric coated caplets)

NF0462T_CEF-1 2.png
Bioclinic Naturals 5-HTP 100mg (60 enteric coated caplets) - supplement facts.JPG
NF0462T_CEF-1 2.png
Bioclinic Naturals 5-HTP 100mg (60 enteric coated caplets) - supplement facts.JPG

Bioclinic Naturals 5-HTP 100mg (60 enteric coated caplets)

0.00

Benefits

  • Naturally sourced from the seed of African plant Griffonia simplicifolia
  • Unlike L-tryptophan, 5-HTP readily crosses the blood-brain barrier increasing central nervous system synthesis of serotonin11
  • Enteric coated to reduce the likelihood of nausea  
Add To Cart

5-Hydroxytryptophan (5-HTP) is an amino acid that is the middle step between tryptophan and neurotransmitter serotonin. Scientific evidence indicates that low serotonin levels are linked to a number of common conditions, including depression, obesity, headache/migraine and fibromyalgia. 5-HTP boosts serotonin levels and may offer a benefit in conditions linked to low serotonin levels.1

5-HTP may help patients unresponsive to standard antidepressant drugs and some evidence suggests it may be comparable, if not superior, to conventional antidepressants, with fewer side effects.2 Taking 5-HTP can also aid pain syndromes such as migraine and fibromyalgia.3 It is thought both conditions reflect a serotonergic defect. Fibromyalgia suffers have experienced improved symptoms including pain severity, morning stiffness, and sleeplessness with 5-HTP supplementation.3,4,5 5-HTP is known to increase sleep quality, which is critical in those patients suffering from depression or fibromyalgia. In fact, 5-HTP is known to promote and maintain sleep in normal subjects, as well as those experiencing insomnia.6  

Research has indicated that 5-HTP may aid weight loss. Early animal studies indicated that genetically obese rats had decreased activity of the enzyme that converts tryptophan to 5-HTP and subsequently serotonin, allowing them to over eat.7 The same mechanism exists in genetically predisposed humans. By providing preformed 5-HTP, this genetic defect is bypassed and more serotonin is manufactured. Human clinical trials have corroborated that 5-HTP is able to reduce caloric intake, promote satiety and induce weight loss without conscious effort by subjects to lose weight.8,9,10  

 

  1. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998;3(4):271-80.
  2. Poldinger W, Calanchini B, Schwarz W. A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine. Psychopathology. 1991;24(2):53-81.
  3. Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. Adv Exp Med Biol. 1996;398:373-9.
  4. Sarzi Puttini P, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J Int Med Res. 1992;20(2):182-9.
  5. Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1990 May-Jun;18(3):201-9.
  6. Wyatt RJ, Zarcone V, Engelman K, Dement WC, Snyder F, Sjoerdsma A. Effects of 5-hydroxytryptophan on the sleep of normal human subjects. Electroencephalogr Clin Neurophysiol. 197 Jun;30(6):505-9.
  7. Wurtman RJ, Wurtman JJ. Brain serotonin, carbohydrate-craving, obesity and depression. Adv Exp Med Biol. 1996;398:35-41.
  8. Ceci F, Cangiano C, Cairella M, Cascino A, Del Ben M, Muscaritoli M, Sibilia L, Rossi-Fanelli F. The effects of oral 5-hydroxytryptophan administration on feeding behaviour in obese adult female subjects. J Neural Transm. 1989;76(2):109-117.
  9. Cangiano C, Ceci F, Cairella M, Cascino A, Del Ben M, Laviano A, Muscaritoli M, Rossi-Fanelli F. Effects of 5-hydroxytryptophan on eating behaviour and adherence to dietary prescriptions in obese adult subjects. Adv Exp Med Biol. 1991;294: 591-593.
  10. Cangiano C, Ceci F, Cascino A, Del Ben M, Laviano A, Muscaritoli M, Antonucci F, Rossi-Fanelli F. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan, Am J Clin Nutr. 56: 863-867;1992.
  11. Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev. 2002;(1):CD003198.
  12. Singhal AB, Caviness VS, Begleiter AF, Mark EJ, Rordorf G, Koroshetz WJ. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology. 2002 Jan 8;58(1):130-3.
  13. Sternberg EM, Van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland CK. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med. 1980 Oct 2;303(14):782-7.
  14. Joly P, Lampert A, Thomine E, Lauret P. Development of pseudobullous morphea and scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. J Am Acad Dermatol. 1991 Aug;25(2 Pt 1):332-3.